Russian lab unveils when first patients will receive cancer vaccine

Personalized treatment is expected to begin “within months,” according to the Gamaleya Center chief

Russia’s first patients could begin receiving a newly developed cancer vaccine within the next few months, Alexander Gintsburg, director of the Gamaleya Research Institute of Epidemiology and Microbiology, has announced. The breakthrough drug is a personalized, AI-assisted, mRNA-based vaccine designed to target malignant tumors using the patient’s own genetic data.